Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTE4KHA)

• DTT Name: Amyloid beta A4 protein (APP)
• Synonyms: Protease nexin-II; PreA4; PN-II; Cerebral vascular amyloid peptide; CVAP; Amyloid-beta precursor protein; Amyloid-beta A4 protein; Alzheimer disease amyloid protein; APPI; APP; AD1; ABPP; A4
• Gene Name: APP
• DTT Type: Successful target; [1]
• Related Disease: Diagnostic imaging [ICD-11: N.A.]
• BioChemical Class: Amyloid beta-protein peptide
• UniProt ID: A4_HUMAN
• TTD ID: T87024
• Sequence:
  MLPGLALLLLAAWTARALEVPTDGNAGLLAEPQIAMFCGRLNMHMNVQNGKWDSDPSGTK
  TCIDTKEGILQYCQEVYPELQITNVVEANQPVTIQNWCKRGRKQCKTHPHFVIPYRCLVG
  EFVSDALLVPDKCKFLHQERMDVCETHLHWHTVAKETCSEKSTNLHDYGMLLPCGIDKFR
  GVEFVCCPLAEESDNVDSADAEEDDSDVWWGGADTDYADGSEDKVVEVAEEEEVAEVEEE
  EADDDEDDEDGDEVEEEAEEPYEEATERTTSIATTTTTTTESVEEVVREVCSEQAETGPC
  RAMISRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAMSQSLLKTTQEPLARD
  PVKLPTTAASTPDAVDKYLETPGDENEHAHFQKAKERLEAKHRERMSQVMREWEEAERQA
  KNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITAL
  QAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYER
  MNQSLSLLYNVPAVAEEIQDEVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTET
  KTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLTN
  IKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIATVIVITL
  VMLKKKQYTSIHHGVVEVDAAVTPEERHLSKMQQNGYENPTYKFFEQMQN
• Function: Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis. Involved in cell mobility and transcription regulation through protein-protein interactions. Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb. Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP. Inhibits G(o) alpha ATPase activity (By similarity). Acts as a kinesin I membrane receptor, mediating the axonal transport of beta-secretase and presenilin 1. Involved in copper homeostasis/oxidative stress through copper ion reduction. In vitro, copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation. Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV. The splice isoforms that contain the BPTI domain possess protease inhibitor activity. Induces a AGER-dependent pathway that involves activation of p38 MAPK, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons. Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1.
• Reactome Pathway:
  Degradation of the extracellular matrix (R-HSA-1474228)
  Regulated proteolysis of p75NTR (R-HSA-193692)
  NRIF signals cell death from the nucleus (R-HSA-205043)
  Activated NOTCH1 Transmits Signal to the Nucleus (R-HSA-2122948)
  Constitutive Signaling by NOTCH1 PEST Domain Mutants (R-HSA-2644606)
  Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants (R-HSA-2894862)
  EPH-ephrin mediated repulsion of cells (R-HSA-3928665)
  Nuclear signaling by ERBB4 (R-HSA-1251985)
• BioCyc Pathway: MetaCyc:ENSG00000142192-MON

Molecular Interaction Atlas (MIA) of This DTT

1 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Florbetapir F-18	DMJ8A3Z	Diagnostic imaging	N.A.	Approved	[1]

31 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ALZT-OP1	DMG5BTD	Alzheimer disease	8A20	Phase 3	[2]
Bapineuzumab	DMHQ5GK	Alzheimer disease	8A20	Phase 3	[3]
BIIB037	DM51JW4	Alzheimer disease	8A20	Phase 3	[4]
Crenezumab	DM7QI29	Alzheimer disease	8A20	Phase 3	[5]
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[6]
Gantenerumab	DMWX90U	Alzheimer disease	8A20	Phase 3	[7], [2]
NI-101	DMJ2KIE	Alzheimer disease	8A20	Phase 3	[8]
PF-03084014	DMUP5Z0	Desmoid tumour	2F7C	Phase 3	[9]
Solanezumab	DM0HIU5	Alzheimer disease	8A20	Phase 3	[10]
Tramiprosate	DM7BSRH	Alzheimer disease	8A20	Phase 3	[11]
CAD-106	DM31VZT	Alzheimer disease	8A20	Phase 2/3	[12]
ALZ-801	DM7ZQAT	Alzheimer disease	8A20	Phase 2	[13]
AN-1792	DM3JNXS	Alzheimer disease	8A20	Phase 2	[14]
BAN2401	DMW03YD	Alzheimer disease	8A20	Phase 2	[15]
FRM-0962	DM9ORUW	Alzheimer disease	8A20	Phase 2	[16]
GSK933776A	DMX27Q1	Alzheimer disease	8A20	Phase 2	[17]
Myo-inositol	DMQKSGI	Alzheimer disease	8A20	Phase 2	[18]
NIC5-15	DMG7XOC	Alzheimer disease	8A20	Phase 2	[19]
Ponezumab	DMIAZ13	Alzheimer disease	8A20	Phase 2	[20]
T-817MA	DMD72F4	Alzheimer disease	8A20	Phase 2	[7], [2]
UB-311	DM4NXWE	Alzheimer disease	8A20	Phase 2	[21]
ACI-24	DM5YDSU	Alzheimer disease	8A20	Phase 1/2	[22]
EB-101	DMH2NKD	Dystrophic epidermolysis bullosa	EC32	Phase 1/2	[5]
11C-6-Me-BTA-1	DMICUPT	Alzheimer disease	8A20	Phase 1	[23]
11C-AZD-2184	DMYVDXW	Alzheimer disease	8A20	Phase 1	[24]
AAB-003/PF-05236812	DM92RQT	Alzheimer disease	8A20	Phase 1	[5]
Affitope AD-01	DM0I8RZ	Alzheimer disease	8A20	Phase 1	[25]
Anti-N3pG-Abeta antibody	DMRWI7E	Alzheimer disease	8A20	Phase 1	[26]
DWP-09031	DM4XZY9	Alzheimer disease	8A20	Phase 1	[5]
SAR228810	DMTFAGU	Alzheimer disease	8A20	Phase 1	[27]
Systebryl	DMD23AX	Amyloidosis	5D00	Phase 1	[5]

3 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Affitope AD-02	DMSF5VK	Alzheimer disease	8A20	Discontinued in Phase 2	[28]
RN6G	DM5P1KQ	Age-related macular degeneration	9B75.0	Discontinued in Phase 2	[29]
PF-05236812	DM68PYA	Alzheimer disease	8A20	Discontinued in Phase 1	[4]

3 Preclinical Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AAB-002	DMC7EQT	Alzheimer disease	8A20	Phase 0	[5]
NN-818	DMLNYGX	Brain injury	NA07.Z	Preclinical	[5]
Pepticlere	DMA5T3J	Alzheimer disease	8A20	Preclinical	[30]

66 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
1,6-bis(4'-aminophenyl)-hexa-1,3,5-triene	DM70ODN	Discovery agent	N.A.	Investigative	[31]
1,6-bis(4'-dimethylaminophenyl)-hexa-1,3,5-triene	DMBCU6W	Discovery agent	N.A.	Investigative	[31]
1,6-Bis(4'-hydroxyphenyl)-hexa-1,3,5-triene	DMEU3MN	Discovery agent	N.A.	Investigative	[31]
1,6-bis(4'-methylaminophenyl)-hexa-1,3,5-triene	DM0D6JN	Discovery agent	N.A.	Investigative	[31]
1,6-bis(4'-nitrophenyl)-hexa-1,3,5-triene	DMQY75B	Discovery agent	N.A.	Investigative	[31]
11A1	DMFVP6K	Alzheimer disease	8A20	Investigative	[5]
123I-DRM-106	DMW172Q	Alzheimer disease	8A20	Investigative	[5]
18F-AV-45 dimer	DMAPI2G	Cerebral amyloid angiopathy	5D00.0	Investigative	[5]
2,5-bis(2-methoxyphenyl)thiophene	DMU5GKN	Discovery agent	N.A.	Investigative	[32]
2,5-bis(4-Hydroxyphenyl)thiophene	DMNQIGZ	Discovery agent	N.A.	Investigative	[32]
2,5-bis(4-methoxyphenyl)thiophene	DM30RNY	Discovery agent	N.A.	Investigative	[32]
2,5-bis(4-nitrophenyl)thiophene	DM3USOR	Discovery agent	N.A.	Investigative	[32]
2-(4-(methylamino)phenyl)benzo[d]thiazol-6-ol	DMFNQZS	Discovery agent	N.A.	Investigative	[31]
2-(4-nitrophenyl)-5-(4-methoxyphenyl)thiophene	DMX8U32	Discovery agent	N.A.	Investigative	[32]
4-(5-(4-(methylamino)phenyl)thiophen-2-yl)phenol	DMGHVW7	Discovery agent	N.A.	Investigative	[32]
4-(5-(4-aminophenyl)thiophen-2-yl)benzenamine	DMOGMJ9	Discovery agent	N.A.	Investigative	[32]
4-(5-(4-aminophenyl)thiophen-2-yl)phenol	DM1UX89	Discovery agent	N.A.	Investigative	[32]
4-(5-(4-methoxyphenyl)thiophen-2-yl)benzenamine	DMO9YH0	Discovery agent	N.A.	Investigative	[32]
4-(5-(4-methoxyphenyl)thiophen-2-yl)phenol	DMCNLBZ	Discovery agent	N.A.	Investigative	[32]
5-hydroxy-2-(4-aminophenyl)benzofuran	DM8KON3	Discovery agent	N.A.	Investigative	[33]
5-hydroxy-2-(4-dimethylaminophenyl)benzofuran	DMYL0ZF	Discovery agent	N.A.	Investigative	[33]
5-hydroxy-2-(4-methylaminophenyl)benzofuran	DM4QC0R	Discovery agent	N.A.	Investigative	[33]
5-methoxy-2-(4-aminophenyl)benzofuran	DMW7IXL	Discovery agent	N.A.	Investigative	[33]
5-methoxy-2-(4-dimethylaminophenyl)benzofuran	DM3NUMG	Discovery agent	N.A.	Investigative	[33]
5-methoxy-2-(4-methylaminophenyl)benzofuran	DM5N1JX	Discovery agent	N.A.	Investigative	[33]
6-iodo-4'-dimethyaminoflavone	DMAL1UH	Discovery agent	N.A.	Investigative	[34]
6-iodo-4'-hydroxyflavone	DM5FZBI	Discovery agent	N.A.	Investigative	[34]
6-iodo-4'-methoxyflavone	DM6U9CY	Discovery agent	N.A.	Investigative	[34]
6-iodo-4'-methylaminoflavone	DM9GJAY	Discovery agent	N.A.	Investigative	[34]
A-887755	DM8IWUE	Alzheimer disease	8A20	Investigative	[5]
Abloid	DMKN10X	Alzheimer disease	8A20	Investigative	[5]
ACI-636	DMPLNTM	Alzheimer disease	8A20	Investigative	[5]
ACU-0101979	DM7ZWRN	Alzheimer disease	8A20	Investigative	[5]
AD-0802	DM23QND	Alzheimer disease	8A20	Investigative	[5]
ANA-5	DM3DPSO	Alzheimer disease	8A20	Investigative	[5]
Anticalin	DMQJ3ZL	Alzheimer disease	8A20	Investigative	[5]
ARC-069	DMSM1PV	Alzheimer disease	8A20	Investigative	[5]
ARN-2966	DMBE0H8	Alzheimer disease	8A20	Investigative	[5]
AS-602704	DMANU3W	Discovery agent	N.A.	Investigative	[35]
AZ4800	DMATC5P	Discovery agent	N.A.	Investigative	[36]
BAN-2203	DMX6KTO	Alzheimer disease	8A20	Investigative	[5]
CD45RB	DMFQVLW	Glioma	2A00.0	Investigative	[5]
Chrysamine -G	DMLEXN0	Discovery agent	N.A.	Investigative	[6]
CT-003230	DM3W6PQ	Cognitive impairment	6D71	Investigative	[5]
DBT-1339	DM09YI7	Alzheimer disease	8A20	Investigative	[5]
DEHYDROZINGERONE	DM9TWR7	Discovery agent	N.A.	Investigative	[6]
EDN-OL1	DMHCGIS	Alzheimer disease	8A20	Investigative	[5]
ELND-007	DM5G1SF	Alzheimer disease	8A20	Investigative	[37]
Gamma-secretase modulators	DMG7UPR	Alzheimer disease	8A20	Investigative	[5]
Gelsolin	DML0OUY	Discovery agent	N.A.	Investigative	[38]
IN-N01	DMI5N23	Brain injury	NA07.Z	Investigative	[5]
KMS-88009	DM2K81B	Alzheimer disease	8A20	Investigative	[5]
KNX-Monoclonal204	DMNWXCA	Alzheimer disease	8A20	Investigative	[5]
Methionine Sulfoxide	DMKE18W	Discovery agent	N.A.	Investigative	[39]
Mimovax	DM7DT20	Alzheimer disease	8A20	Investigative	[5]
PA-1637	DMUH203	Neurological disorder	6B60	Investigative	[5]
RECALL-VAX	DM1XFE9	Alzheimer disease	8A20	Investigative	[5]
SB-13	DM9O0AR	Discovery agent	N.A.	Investigative	[31]
SEM-606	DMDIZUT	Neurological disorder	6B60	Investigative	[5]
SEN-1500	DMKB2IJ	Alzheimer disease	8A20	Investigative	[5]
SP-08	DM2TRIZ	Alzheimer disease	8A20	Investigative	[5]
SR-973	DMU48OD	Discovery agent	N.A.	Investigative	[40]
TKP-1001	DMDBUXR	Alzheimer disease	8A20	Investigative	[5]
Turmeric extracts	DM3QE8P	Alzheimer disease	8A20	Investigative	[5]
VK-11	DM7FQD0	Alzheimer disease	8A20	Investigative	[5]
VK-12	DMRQBEW	Solid tumour/cancer	2A00-2F9Z	Investigative	[5]

Molecular Expression Atlas (MEA) of This DTT

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Alzheimer's disease	8A00.0	Entorhinal cortex	1.60E-02	-0.07	-0.31
Breast cancer	2C82	Breast tissue	4.56E-07	0.34	0.44
Glioma	2C82	Brainstem tissue	7.29E-01	-0.07	-0.13
Glioma	2C82	White matter	1.34E-04	-0.51	-1.73
Parkinson's disease	8A00.0	Substantia nigra tissue	2.13E-01	-0.03	-0.06

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Bapineuzumab: anti-beta-amyloid monoclonal antibodies for the treatment of Alzheimer's disease. Immunotherapy. 2010 Nov;2(6):767-82.
• [4] Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets . Immun Ageing. 2013; 10: 18.
• [5] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2402).
• [6] Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for beta-amyloid plaque imaging. J Med Chem. 2006 Oct 5;49(20):6111-9.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Disease-modifying drugs in Alzheimer's disease. Drug Des Devel Ther. 2013; 7: 1471-1479.
• [9] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [10] Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):311-21.
• [11] Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007 Apr;28(4):537-47.
• [12] The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011 Jun 22;31(25):9323-31.
• [13] Oral Clinical Candidate ALZ-801 in Alzheon's pipeline. 2012.
• [14] Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol. 2006 Sep;169(3):1048-63.
• [15] The murine version of BAN2401 (mAb158) selectively reduces amyloid-beta protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice. J Alzheimers Dis. 2015;43(2):575-88.
• [16] Gamma-secretase. SciBX 7(40); doi:10.1038/scibx.2014.1175. Oct. 16 2014
• [17] Profile of gantenerumab and its potential in the treatment of Alzheimer's disease. Correction in: Drug Des Devel Ther. 2014; 8: 569.
• [18] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [19] Combating neurodegenerative disease with chemical probes and model systems. Nat Chem Biol. 2014 Nov;10(11):911-20.
• [20] Structural basis of C-terminal beta-amyloid peptide binding by the antibody ponezumab for the treatment of Alzheimer's disease. J Mol Biol. 2012 Aug 24;421(4-5):525-36.
• [21] Active immunotherapy options for Alzheimer's disease. Alzheimers Res Ther. 2014; 6(1): 7.
• [22] Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener. 2013; 8: 36.
• [23] Radiosynthesis and evaluation of [11C]BTA-1 and [11C]3'-Me-BTA-1 as potential radiotracers for in vivo imaging of beta-amyloid plaques. Nuklearmedizin. 2007;46(6):271-80.
• [24] Low background and high contrast PET imaging of amyloid-beta with [11C]AZD2995 and [11C]AZD2184 in Alzheimer's disease patients. Eur J Nucl Med Mol Imaging. 2013 April; 40(4): 580-593.
• [25] Alzheimer's Disease and the Amyloid Cascade Hypothesis: A Critical Review. Int J Alzheimers Dis. 2012; 2012: 369808.
• [26] LY3002813 Alzheimer's Disease (Phase 1). Eli Lilly & Co.
• [27] SAR228810: An antiprotofibrillar beta-amyloid antibody designed to reduce risk of amyloid-related imaging abnormalities (ARIA). Alzheimer's & Dementia Volume 9, Issue 4, Supplement, July 2013, Pages P808-P809.
• [28] Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward. Expert Rev Clin Immunol. 2014 Mar;10(3):405-19.
• [29] Advances in the management of macular degeneration. F1000Prime Rep. 2014; 6: 29.
• [30] Preclinical trail of Pepticlere (DP-74) for treating Alzheimer's disease. ProteoTech Inc.
• [31] Synthesis of biphenyltrienes as probes for beta-amyloid plaques. J Med Chem. 2006 May 4;49(9):2841-4.
• [32] Design, synthesis, and structure-activity relationship of novel thiophene derivatives for beta-amyloid plaque imaging. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1350-2.
• [33] Novel benzofuran derivatives for PET imaging of beta-amyloid plaques in Alzheimer's disease brains. J Med Chem. 2006 May 4;49(9):2725-30.
• [34] Radioiodinated flavones for in vivo imaging of beta-amyloid plaques in the brain. J Med Chem. 2005 Nov 17;48(23):7253-60.
• [35] Transport characteristics of a beta sheet breaker peptide across excised bovine nasal mucosa. Drug Dev Ind Pharm. 2007 Jan;33(1):71-7.
• [36] First and second generation gamma-secretase modulators (GSMs) modulate amyloid-beta (Abeta) peptide production through different mechanisms. J Biol Chem. 2012 Apr 6;287(15):11810-9.
• [37] Inhibition of APP gamma-secretase restores Sonic Hedgehog signaling and neurogenesis in the Ts65Dn mouse model of Down syndrome. Neurobiology of Disease Volume 82, October 2015, Pages 385-396.
• [38] Novel therapeutic approach for the treatment of Alzheimer's disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci. 2003 Jan 1;23(1):29-33.
• [39] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [40] Synthesis and evaluation of succinoyl-caprolactam gamma-secretase inhibitors. Bioorg Med Chem Lett. 2006 May 1;16(9):2357-63.